Ann: Notification of cessation of securities - PAB, page-8

Remember this? A new study featuring Patrys’ (PAB) PAT-DX1 candidate demonstrates its ability to inhibit the growth of primary and secondary brain cancersData from the study highlights the drug’s ability to selectively kill cancer cells by blocking their DNA damage repair systemsThe treatment has also been found to extend the median survival rate for two different brain cancersFindings from the study have been published in The Journal of Clinical Investigation—InsightPatrys shares are up 7.32 per cent and trading at 4.4 cents at 12.13 pm AEST